Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 277 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Varenicline (Chantix) Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Switch or Quit R01

NCT06373679
View directory record Official record
Conditions
Cigarette Smoking, Smoking Behaviors
Interventions
Switching to E-Cigarette, Switching using Medication
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 30, 2026, 5:52 AM EDT
Recruiting Phase 2 Interventional

Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse

NCT06609369
View directory record Official record
Conditions
Tobacco Use, Tobacco Cessation, Insomnia
Interventions
Experimental health intervention, Varenicline
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Phase 2 Interventional

Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3

NCT00992771
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 3
Interventions
varenicline, placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Los Angeles, California • Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2012 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Phase 4 Interventional

Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray

NCT05514041
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Varenicline solution, Placebo nasal spray (OC-01 Vehicle Nasal Spray)
Drug
Lead sponsor
Stephenson Eye Associates
Other
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Venice, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Phase 3 Interventional

An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation

NCT00143325
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline (CP-526,555)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Palo Alto, California • Santa Ana, California • Farmington, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2007 · Synced Sep 30, 2026, 5:52 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants

NCT01560507
View directory record Official record
Conditions
Cigarette Smoking, Nicotine Dependence
Interventions
varenicline (Chantix), bupropion (Zyban), nicotine patches
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

NCT01456936
View directory record Official record
Conditions
Smoking Cessation
Interventions
Placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
8,144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
77
States / cities
Mobile, Alabama • Phoenix, Arizona • Encino, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2016 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Not applicable Interventional Results available

Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients

NCT01378858
View directory record Official record
Conditions
Tobacco Use Disorder, Medication Adherence
Interventions
Varenicline
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Sep 30, 2026, 5:52 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL

NCT05136924
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo, Placebo (vehicle) nasal spray
Drug · Other
Lead sponsor
Vance Thompson Vision - MT
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Sep 30, 2026, 5:52 AM EDT
Terminated Phase 2 Interventional Results available

Pre to Postoperative Smoking Cessation

NCT02683161
View directory record Official record
Conditions
Cigarette Smoking, Obesity
Interventions
Varenicline, Contingency Management, Behavioral Counseling
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 30, 2026, 5:52 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

A Stepped Care Approach to Treating Tobacco Use in Rural Veterans

NCT04501016
View directory record Official record
Conditions
Tobacco Cessation
Interventions
Tailored behavioral counseling, Tobacco cessation pharmacotherapy
Behavioral · Drug
Lead sponsor
Iowa City Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Not applicable Interventional Results available

Smoking Cessation Using Motivational Therapy and Varenicline

NCT00701896
View directory record Official record
Conditions
Smoking, HIV Infections
Interventions
Varenicline tartrate, Nicotine Replacement Therapy, Biological Control, Motivational Interview
Drug · Other · Behavioral
Lead sponsor
Philip Diaz
Other
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Phase 4 Interventional Results available

Varenicline Effects In Schizophrenic Smokers

NCT00548470
View directory record Official record
Conditions
Schizophrenia, Tobacco Use Disorder, Nicotine Dependance
Interventions
Varenicline
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03636061
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Not applicable Interventional

Varenicline Tartrate With Telephone-Based Counseling and/or Internet-Based Counseling in Helping Adults Stop Smoking

NCT00301145
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
smoking cessation intervention, varenicline, counseling intervention, internet-based intervention
Behavioral · Drug · Other
Lead sponsor
SRI International
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Menlo Park, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Varenicline: Testing Individual Differences

NCT01228175
View directory record Official record
Conditions
Smoking Addiction
Interventions
Placebo, Varenicline
Drug
Lead sponsor
The Mind Research Network
Other
Eligibility
18 Years to 55 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Sep 30, 2026, 5:52 AM EDT
Recruiting Not applicable Interventional

Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network

NCT06582693
View directory record Official record
Conditions
Smoking, Smoking Cessation, Second Hand Tobacco Smoke
Interventions
Refer2Quit
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

EVarQuit: Extended Pre-quit Varenicline to Assist in Quitting Smoking

NCT03262662
View directory record Official record
Conditions
Tobacco Smoking
Interventions
Varenicline, Brief smoking cessation counseling
Drug · Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 70 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Phase 1 Interventional

Multiple Dose, Dose Escalation Study of Varenicline Controlled Release Formulation in Adult Smokers

NCT00527150
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline Tartrate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Sep 30, 2026, 5:52 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Human Behavioral Pharmacology Laboratory Study of Varenicline's Impact on Cocaine Reinforcement

NCT01143857
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Varenicline
Drug
Lead sponsor
Jennifer Plebani
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2013 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Phase 2 Interventional

12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation

NCT00150228
View directory record Official record
Conditions
Smoking Cessation
Interventions
CP-526,555 (varenicline)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
7
States / cities
Lexington, Kentucky • Albert Lea, Minnesota • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2007 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Not applicable Interventional

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use

NCT04694846
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
Nicotine Replacement, Bupropion Hydrochloride Controlled-release, Varenicline, Tobacco Cessation Counseling, Questionnaire Administration, Quality of Life Assessment, Best Practice
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cessation Screening Project

NCT04188873
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Preparation Varenicline and Standard Duration Varenicline, Preparation Varenicline and Extended Duration Varenicline, Standard Duration Varenicline, Extended Duration Varenicline, Preparation Combination NRT and Standard Duration Combination NRT, Preparation Combination NRT and Extended Duration Combination NRT, Standard Duration Combination NRT, Extended Duration Combination NRT, Intensive Counseling, Minimal Counseling
Drug · Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 30, 2026, 5:52 AM EDT
Completed Phase 4 Interventional Results available

Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers

NCT02378714
View directory record Official record
Conditions
Nicotine Dependence, Major Depressive Disorder
Interventions
Varenicline, BASC, Standard treatment
Drug · Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 30, 2026, 5:52 AM EDT